Research Papers: Pathology:

The pathological role of advanced glycation end products-downregulated heat shock protein 60 in islet β-cell hypertrophy and dysfunction

Siao-Syun Guan, Meei-Ling Sheu, Rong-Sen Yang, Ding-Cheng Chan, Cheng-Tien Wu, Ting-Hua Yang, Chih-Kang Chiang and Shing-Hwa Liu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:23072-23087. https://doi.org/10.18632/oncotarget.8604

Metrics: PDF 1178 views  |   HTML 1893 views  |   ?  


Siao-Syun Guan1,2,*, Meei-Ling Sheu3,*, Rong-Sen Yang4,*, Ding-Cheng Chan5,*, Cheng-Tien Wu1, Ting-Hua Yang6, Chih-Kang Chiang1,7 and Shing-Hwa Liu1,8,9

1 Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan

2 Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, Taoyuan, Taiwan

3 Biomedical Sciences, College of Life Sciences, National Chung Hsing University, Taichung, Taiwan

4 Department of Orthopaedics, College of Medicine, National Taiwan University, Taipei, Taiwan

5 Department of Geriatrics and Gerontology, College of Medicine, National Taiwan University, Taipei, Taiwan

6 Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan

7 Department of Integrated Diagnostics and Therapeutics and Internal Medicine, College of Medicine and Hospital, National Taiwan University, Taipei, Taiwan

8 Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan

9 Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan

* These authors have contributed equally to this work

Correspondence to:

Shing-Hwa Liu, email:

Chih-Kang Chiang, email:

Keywords: diabetes, advanced glycation end products, β-cell hypertrophy, heat shock protein 60, Pathology Section

Received: March 16, 2016 Accepted: March 29, 2016 Published: April 05, 2016


Heat shock protein 60 (HSP60) is a mitochondrial chaperone. Advanced glycation end products (AGEs) have been shown to interfere with the β-cell function. We hypothesized that AGEs induced β-cell hypertrophy and dysfunction through a HSP60 dysregulation pathway during the stage of islet/β-cell hypertrophy of type-2-diabetes. We investigated the role of HSP60 in AGEs-induced β-cell hypertrophy and dysfunction using the models of diabetic mice and cultured β-cells. Hypertrophy, increased levels of p27Kip1, AGEs, and receptor for AGEs (RAGE), and decreased levels of HSP60, insulin, and ATP content were obviously observed in pancreatic islets of 12-week-old db/db diabetic mice. Low-concentration AGEs significantly induced the cell hypertrophy, increased the p27Kip1 expression, and decreased the HSP60 expression, insulin secretion, and ATP content in cultured β-cells, which could be reversed by RAGE neutralizing antibody. HSP60 overexpression significantly reversed AGEs-induced hypertrophy, dysfunction, and ATP reduction in β-cells. Oxidative stress was also involved in the AGEs-decreased HSP60 expression in β-cells. Pancreatic sections from diabetic patient showed islet hypertrophy, increased AGEs level, and decreased HSP60 level as compared with normal subject. These findings highlight a novel mechanism by which a HSP60-correlated signaling pathway contributes to the AGEs-RAGE axis-induced β-cell hypertrophy and dysfunction under diabetic hyperglycemia.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8604